Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

RegulatoryapprovedHBM7004Positive

AI Analysis

Summary

Harbour BioMed announced NMPA approval of its IND application for HBM7004, an antibody therapeutic candidate for treating advanced solid tumors, enabling clinical development in China.

Outcome Details

NMPA approval of IND application

Importance:5/10

Sentiment:

0.70

oncologyantibody therapeuticsIND approvalNMPAChina

Related Companies

$DFPH $GBCYD $SLDB

Read the original article

Published by PR Newswire Biotech on August 18, 2026 9:02 AM

Read Original